Yu Chen, MD, PhD

About Me

As a physician-scientist and board-certified medical oncologist. I am devoted to the care of cancer patients in the clinic and to gaining knowledge in the laboratory of how cancers develop. My research focus is on the pathogenesis and treatment of prostate cancer. I am involved in a multidisciplinary effort with oncologists, pathologist, and surgeons to analyze tumor tissues and to develop clinical trials. My laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on the study of critical drivers in prostate cancer pathogenesis using cell, tissue, and mouse models.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
  • Clinical Expertise: Prostate Cancer; Bladder Cancer
  • Languages Spoken: English
  • Education: MD, Cornell University Medical College
  • Residencies: Internal Medicine - Brigham and Women's Hospital
  • Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine, Medical Oncology

My Research

View my lab

See Yu Chen’s laboratory
research at Memorial Sloan Kettering.

See My Colleagues


Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P.. Visualization of the interstitial cells of cajal (ICC) network in mice. J Vis Exp Dec 31, 2011; 53 :

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.. Cancer Cell 2011; 19 :575-86

Chen Y., Arora, V.K. Sawyers C.L. (2011). Molecular Biology of Prostate Cancer. In: Devita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia: Lippincott Williams & Wilkins.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010; 467 :849-53

Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.. Cancer Cell 2010; 17 :415-6

Chen Y, Clegg NJ, Scher HI.. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology 2009; 10 :981-91

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.. Science 2009; 324 :787-90

Welsbie D, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 2009; 69 :958-66

Chen Y, Sawyers CL, Scher HI.. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 :440-448

Chen Y, Sawyers CL. Molecular Biology of Prostate Cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1385-91.

Ghia KK, Chen Y, Milner DA Jr, Fisher DC. Challenging manifestations of malignancies. Case 2. Langerhans cell histiocytosis presenting with a skin rash.. Journal of Clinical Oncology 2004; 22 :3640-3642

Rajagopal A, Pant AC, Simon SM, Chen Y.. In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.. Cancer Research 2002; 62 :391-396

Chen Y, Pant AC, Simon SM.. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.. Cancer Research 2001; 61 :391-396

Chen Y, Simon SM.. In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.. The Journal of Cell Biology 2000; 148 :863-879

Chen Y, Schindler M, Simon SM.. A mechanism for tamoxifen-mediated inhibition of acidification. Journal of Biological Chemistry 1999; 274 :18364-18373

Altan N, Chen Y, Schindler M, Simon SM.. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. . Proceedings of the National Academy of Sciences of the United States of America 1999; 96 :44432-4438

Altan N, Chen Y, Schindler M, Simon SM.. Defective acidification in human breast tumor cells and implications for chemotherapy. Journal of Experimental Medicine 1998; 187 :1583-1598

Chen Y, Gross P, Ramakrishna V, Rabitz H, Mease K, Singh H. Control of classical regime molecular objectives - applications of tracking and Variations of the theme. Automatica 1997; 33 :1617-1633

Chen Y., Gross P., Ramakrishn V., Rabitz H., Mease K., Singh H. Selective excitation of molecular eigenstates using state-dependent optical field design. Chemical Physics Letters 1996; 252 :447-456

Chen Y, Gross P, Ramakrishna V, Rabitz H., Mease K, Singh H. Competitive tracking of molecular objectives described by quantum mechanics. Journal of Chemical Physics 1995; 102 :8001-8010


Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more